
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Free Report) – Equities research analysts at HC Wainwright raised their FY2026 earnings estimates for Orchestra BioMed in a research report issued on Friday, November 13th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($1.37) per share for the year, up from their prior estimate of ($1.52). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q4 2026 earnings at ($0.36) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.32) EPS, Q4 2027 earnings at ($0.32) EPS and FY2027 earnings at ($1.29) EPS.
A number of other brokerages have also recently weighed in on OBIO. Weiss Ratings upgraded shares of Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. B. Riley Financial increased their target price on shares of Orchestra BioMed from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a research report on Friday, October 23rd. Piper Sandler reissued an “overweight” rating on shares of Orchestra BioMed in a research note on Thursday, October 15th. Finally, BTIG Research boosted their price target on shares of Orchestra BioMed from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, November 13th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.29.
Orchestra BioMed Stock Performance
Shares of NASDAQ:OBIO opened at $7.46 on Tuesday. The firm’s 50 day moving average is $5.98 and its two-hundred day moving average is $4.68. Orchestra BioMed has a 52 week low of $3.46 and a 52 week high of $7.83. The company has a debt-to-equity ratio of 4.58, a quick ratio of 7.24 and a current ratio of 7.25.
Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.10. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.13 million. Orchestra BioMed had a negative net margin of 182.50% and a negative return on equity of 186.93%.
Insider Buying and Selling at Orchestra BioMed
In other Orchestra BioMed news, Director Eric S. Fain acquired 20,000 shares of Orchestra BioMed stock in a transaction dated Monday, November 9th. The stock was bought at an average price of $5.00 per share, for a total transaction of $100,000.00. Following the transaction, the director owned 119,630 shares in the company, valued at approximately $598,150. This trade represents a 20.07% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David P. Hochman acquired 10,000 shares of the stock in a transaction dated Thursday, September 3rd. The stock was acquired at an average cost of $4.79 per share, for a total transaction of $47,900.00. Following the purchase, the insider directly owned 1,070,746 shares in the company, valued at approximately $5,128,873.34. The trade was a 0.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 58,000 shares of company stock valued at $288,560 and have sold 45,000 shares valued at $255,600. 7.50% of the stock is owned by corporate insiders.
Institutional Trading of Orchestra BioMed
A number of hedge funds and other institutional investors have recently made changes to their positions in OBIO. Goldman Sachs Group Inc. grew its position in Orchestra BioMed by 112.8% in the third quarter. Goldman Sachs Group Inc. now owns 382,160 shares of the company’s stock worth $2,377,000 after buying an additional 202,554 shares during the last quarter. Jump Financial LLC bought a new position in shares of Orchestra BioMed in the third quarter valued at $136,000. Empowered Funds LLC bought a new position in shares of Orchestra BioMed in the third quarter valued at $450,000. HighTower Advisors LLC lifted its position in shares of Orchestra BioMed by 8.7% during the 3rd quarter. HighTower Advisors LLC now owns 38,462 shares of the company’s stock valued at $239,000 after acquiring an additional 3,087 shares during the last quarter. Finally, Daytona Street Capital LLC lifted its position in shares of Orchestra BioMed by 27.7% during the 3rd quarter. Daytona Street Capital LLC now owns 123,148 shares of the company’s stock valued at $744,000 after acquiring an additional 26,750 shares during the last quarter. 53.20% of the stock is currently owned by institutional investors.
Latest Orchestra BioMed News
Here’s some of the latest news about OBIO:
- Positive Sentiment: HC Wainwright raised its FY2026 and FY2027 EPS estimates, projecting narrower losses of $1.37 and $1.29 per share, respectively, while reiterating a Buy rating and $12 price target. The improved forecasts may support sentiment, although the company is still expected to report losses. MarketBeat analyst estimates
- Neutral Sentiment: Management will participate in the Piper Sandler Healthcare Conference on Dec. 2, with CEO David Hochman scheduled for a fireside chat and investor meetings. This could raise visibility, but the announcement provides no new operating or trial results. Conference announcement
- Negative Sentiment: Orchestra BioMed’s lead candidates, AVIM Therapy and Virtue SAB, remain investigational and are undergoing pivotal clinical trials. Their potential is dependent on clinical progress and eventual regulatory approval, so near-term revenue remains uncertain.
Orchestra BioMed Company Profile
Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices. The company’s lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.
Read More
- Five stocks we like better than Orchestra BioMed
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
